Loading...

Caplin Point Laboratories

NSEI:CAPPL
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CAPPL
NSEI
₹29B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Caplin Point Laboratories Limited produces, develops, markets, and exports generic formulations and branded products in India and internationally. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
CAPPL Share Price and Events
7 Day Returns
-2.4%
NSEI:CAPPL
-0.5%
IN Pharmaceuticals
-1%
IN Market
1 Year Returns
-38%
NSEI:CAPPL
-0.5%
IN Pharmaceuticals
-1.6%
IN Market
CAPPL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Caplin Point Laboratories (CAPPL) -2.4% -6.4% 5.2% -38% 92% -
IN Pharmaceuticals -0.5% 2.1% 2.2% -0.5% -11.4% 34%
IN Market -1% 3% 6.2% -1.6% 39% 73%
1 Year Return vs Industry and Market
  • CAPPL underperformed the Pharmaceuticals industry which returned -0.5% over the past year.
  • CAPPL underperformed the Market in India which returned -1.6% over the past year.
Price Volatility
CAPPL
Industry
5yr Volatility vs Market

CAPPL Value

 Is Caplin Point Laboratories undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Caplin Point Laboratories to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Caplin Point Laboratories.

NSEI:CAPPL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 14.6%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:CAPPL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 35%) (0.02%))
0.82
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.82
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.82 * 8.6%)
14.61%

Discounted Cash Flow Calculation for NSEI:CAPPL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Caplin Point Laboratories is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:CAPPL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 14.61%)
2019 421.44 Est @ 11.62% 367.73
2020 465.27 Est @ 10.4% 354.24
2021 509.69 Est @ 9.55% 338.59
2022 555.29 Est @ 8.95% 321.88
2023 602.65 Est @ 8.53% 304.81
2024 652.27 Est @ 8.23% 287.86
2025 704.65 Est @ 8.03% 271.34
2026 760.21 Est @ 7.89% 255.43
2027 819.39 Est @ 7.78% 240.23
2028 882.60 Est @ 7.71% 225.78
Present value of next 10 years cash flows ₹2,967.87
NSEI:CAPPL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ₹882.60 × (1 + 7.55%) ÷ (14.61% – 7.55%)
₹13,452.55
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹13,452.55 ÷ (1 + 14.61%)10
₹3,441.31
NSEI:CAPPL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹2,967.87 + ₹3,441.31
₹6,409.18
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹6,409.18 / 75.63
₹84.74
NSEI:CAPPL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NSEI:CAPPL represents 0.99748x of BSE:524742
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99748x
Value per Share
(Listing Adjusted, INR)
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 84.74 x 0.99748
₹84.53
Value per share (INR) From above. ₹84.53
Current discount Discount to share price of ₹376.05
= -1 x (₹376.05 - ₹84.53) / ₹84.53
-344.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Caplin Point Laboratories is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Caplin Point Laboratories's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Caplin Point Laboratories's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:CAPPL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in INR ₹21.45
BSE:524742 Share Price ** BSE (2019-04-25) in INR ₹377
India Pharmaceuticals Industry PE Ratio Median Figure of 112 Publicly-Listed Pharmaceuticals Companies 20.04x
India Market PE Ratio Median Figure of 2,739 Publicly-Listed Companies 16.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Caplin Point Laboratories.

NSEI:CAPPL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:524742 Share Price ÷ EPS (both in INR)

= 377 ÷ 21.45

17.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Caplin Point Laboratories is good value based on earnings compared to the IN Pharmaceuticals industry average.
  • Caplin Point Laboratories is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does Caplin Point Laboratories's expected growth come at a high price?
Raw Data
NSEI:CAPPL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 17.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-5.1%per year
India Pharmaceuticals Industry PEG Ratio Median Figure of 33 Publicly-Listed Pharmaceuticals Companies 1.3x
India Market PEG Ratio Median Figure of 586 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Caplin Point Laboratories, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Caplin Point Laboratories's assets?
Raw Data
NSEI:CAPPL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in INR ₹62.13
BSE:524742 Share Price * BSE (2019-04-25) in INR ₹377
India Pharmaceuticals Industry PB Ratio Median Figure of 133 Publicly-Listed Pharmaceuticals Companies 1.9x
India Market PB Ratio Median Figure of 3,630 Publicly-Listed Companies 1.09x
NSEI:CAPPL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:524742 Share Price ÷ Book Value per Share (both in INR)

= 377 ÷ 62.13

6.07x

* Primary Listing of Caplin Point Laboratories.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Caplin Point Laboratories is overvalued based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess Caplin Point Laboratories's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Caplin Point Laboratories has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CAPPL Future Performance

 How is Caplin Point Laboratories expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

  • No analysts cover Caplin Point Laboratories, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-5.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Caplin Point Laboratories expected to grow at an attractive rate?
  • Caplin Point Laboratories's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Caplin Point Laboratories's earnings are expected to decrease over the next 1-3 years, this is below the India market average.
  • Caplin Point Laboratories's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
Raw Data
NSEI:CAPPL Future Growth Rates Data Sources
Data Point Source Value (per year)
NSEI:CAPPL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -5.1%
NSEI:CAPPL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 14.5%
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.8%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 13.4%
India Market Earnings Growth Rate Market Cap Weighted Average 18.3%
India Market Revenue Growth Rate Market Cap Weighted Average 11.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:CAPPL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:CAPPL Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-03-31 7,226 1
2019-03-31 6,283 1
NSEI:CAPPL Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-12-31 6,048 1,621
2018-09-30 5,874 1,538
2018-06-30 5,628 1,459
2018-03-31 5,399 665 1,448
2017-12-31 5,145 1,430
2017-09-30 4,757 1,297
2017-06-30 4,401 1,165
2017-03-31 4,016 676 956
2016-12-31 3,655 783
2016-09-30 3,420 703
2016-06-30 3,238 619
2016-04-01 3,088 565 584

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Caplin Point Laboratories's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Caplin Point Laboratories's revenue is expected to grow by 14.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:CAPPL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Caplin Point Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:CAPPL Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-03-31
2019-03-31
NSEI:CAPPL Past Financials Data
Date (Data in INR Millions) EPS *
2018-12-31 21.45
2018-09-30 20.75
2018-06-30 19.29
2018-03-31 19.16
2017-12-31 18.88
2017-09-30 17.16
2017-06-30 15.42
2017-03-31 12.65
2016-12-31 10.37
2016-09-30 9.32
2016-06-30 8.19
2016-04-01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Caplin Point Laboratories will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Caplin Point Laboratories's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Caplin Point Laboratories has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CAPPL Past Performance

  How has Caplin Point Laboratories performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Caplin Point Laboratories's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Caplin Point Laboratories has delivered over 20% year on year earnings growth in the past 5 years.
  • Caplin Point Laboratories's 1-year earnings growth is less than its 5-year average (13.4% vs 39.8%)
  • Caplin Point Laboratories's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (13.4% vs 16.4%).
Earnings and Revenue History
Caplin Point Laboratories's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Caplin Point Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:CAPPL Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 6,048.27 1,621.19 449.18 236.81
2018-09-30 5,874.07 1,537.75 430.80 236.81
2018-06-30 5,627.90 1,458.84 416.93
2018-03-31 5,399.07 1,447.88 392.30 236.81
2017-12-31 5,144.88 1,429.60 367.20 140.88
2017-09-30 4,756.71 1,296.89 352.15 140.88
2017-06-30 4,400.81 1,165.24 321.67
2017-03-31 4,016.49 956.12 320.87 140.88
2016-12-31 3,655.01 782.66 300.14 54.35
2016-09-30 3,419.80 703.39 274.25 54.35
2016-06-30 3,238.01 619.02 258.26 54.35
2016-04-01 3,088.49 584.14 240.18 54.35
2015-12-31 2,905.59 534.79 297.88 67.08
2015-09-30 2,721.72 465.14 283.46 60.33
2015-06-30 2,517.70 410.37 202.97 58.82
2015-03-31 2,296.00 353.40 233.15 52.72
2014-12-31 2,073.83 318.23 220.28 41.79
2014-09-30 1,892.97 304.88 204.32 33.08
2014-06-30 1,730.89 258.49 190.00 20.80
2014-03-31 1,642.56 204.12 166.48 3.77
2013-12-31 1,517.20 166.99 149.21
2013-09-30 1,408.15 125.37 137.42
2013-06-30 1,270.28 139.84 124.76 6.58
2013-03-31 1,208.73 148.40 115.83
2012-12-31 1,180.07 135.35 112.63
2012-09-30 1,128.87 119.39 110.08
2012-06-30 1,072.17 80.07 103.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Caplin Point Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Caplin Point Laboratories used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
  • Caplin Point Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Caplin Point Laboratories's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Caplin Point Laboratories has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CAPPL Health

 How is Caplin Point Laboratories's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Caplin Point Laboratories's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Caplin Point Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Caplin Point Laboratories's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Caplin Point Laboratories's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 758.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Caplin Point Laboratories Company Filings, last reported 3 months ago.

NSEI:CAPPL Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4,352.43 4.48 1,062.51
2018-09-30 4,352.43 4.48 1,062.51
2018-06-30 3,639.22 3.22 845.01
2018-03-31 3,639.22 5.37 823.97
2017-12-31 2,881.31 3.73 783.61
2017-09-30 2,881.31 3.73 783.61
2017-06-30 2,245.59 4.75 972.75
2017-03-31 2,251.25 7.24 955.09
2016-12-31 1,645.58 5.61 917.65
2016-09-30 1,645.58 5.61 917.65
2016-06-30 1,284.09 20.04 681.02
2016-04-01 1,357.24 20.04 665.52
2015-12-31 1,246.21 5.75 648.39
2015-09-30 934.61 20.91 453.72
2015-06-30 934.61 20.78 453.72
2015-03-31 796.95 15.93 422.85
2014-12-31 796.95 15.93 422.85
2014-09-30 619.16 33.33 268.24
2014-06-30 619.16 33.33 268.24
2014-03-31 558.68 25.76 292.81
2013-12-31 558.68 25.76 292.81
2013-09-30 432.35 46.96 168.38
2013-06-30 432.35 46.96 168.38
2013-03-31 431.30 40.72 275.40
2012-12-31 431.30 40.72 275.40
2012-09-30 336.31 68.82 318.05
2012-06-30 336.31 68.82 318.05
  • Caplin Point Laboratories's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (4.6% vs 0.1% today).
  • Debt is well covered by operating cash flow (14833%, greater than 20% of total debt).
  • Caplin Point Laboratories earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Caplin Point Laboratories's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Caplin Point Laboratories has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CAPPL Dividends

 What is Caplin Point Laboratories's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.53%
Current annual income from Caplin Point Laboratories dividends.
If you bought ₹2,000 of Caplin Point Laboratories shares you are expected to receive ₹11 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Caplin Point Laboratories's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.51%).
  • Caplin Point Laboratories's dividend is below the markets top 25% of dividend payers in India (1.95%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:CAPPL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 69 Stocks 0.7%
India Market Average Dividend Yield Market Cap Weighted Average of 1399 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 1.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:CAPPL Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2020-03-31
2019-03-31
NSEI:CAPPL Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2018-05-28 2.000 0.491
2017-09-21 1.500 0.239
2016-09-12 1.400 0.331
2016-02-05 1.000 0.478
2015-08-20 1.000 0.380
2014-12-22 0.800 0.508
2013-11-07 0.500 1.460
2012-11-09 0.400 3.035
2012-01-05 0.300 5.036
2010-11-22 0.200 4.456

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Caplin Point Laboratories has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Caplin Point Laboratories only paid a dividend in the past 8 years.
Current Payout to shareholders
What portion of Caplin Point Laboratories's earnings are paid to the shareholders as a dividend.
  • Dividends paid are thoroughly covered by earnings (10.7x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Caplin Point Laboratories's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Caplin Point Laboratories afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Caplin Point Laboratories has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CAPPL Management

 What is the CEO of Caplin Point Laboratories's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sridhar Ganesan
COMPENSATION ₹5,689,000
AGE 63
TENURE AS CEO 4.1 years
CEO Bio

Dr. Sridhar Ganesan has been the Managing Director of Caplin Point Laboratories Ltd since March 28, 2015. Dr. Ganesan has been Whole Time Director of Caplin Point Laboratories Ltd since August 25, 2014. Dr. Ganesan served as Non-Executive Independent Director of Caplin Point Laboratories Ltd since February 12, 2014 until August 25, 2014. He holds a MS in Pharmaceuticals and Doctorate in Homeopathic Medicines.

CEO Compensation
  • Sridhar's compensation has been consistent with company performance over the past year.
  • Sridhar's remuneration is lower than average for companies of similar size in India.
Management Team Tenure

Average tenure of the Caplin Point Laboratories management team in years:

4.1
Average Tenure
  • The tenure for the Caplin Point Laboratories management team is about average.
Management Team

Sridhar Ganesan

TITLE
MD & Whole Time Director
COMPENSATION
₹6M
AGE
63
TENURE
4.1 yrs

D. Muralidharan

TITLE
Chief Financial Officer
COMPENSATION
₹2M
TENURE
3.2 yrs

S. Kumar

TITLE
Company Secretary & Compliance Officer
COMPENSATION
₹716K

Partheeban Siddarth

TITLE
Chief Operating Officer
COMPENSATION
₹2M
TENURE
7.7 yrs

V. Natarajan

TITLE
Head of Formulation & Development -Injectibles
Board of Directors Tenure

Average tenure and age of the Caplin Point Laboratories board of directors in years:

4.8
Average Tenure
66
Average Age
  • The tenure for the Caplin Point Laboratories board of directors is about average.
Board of Directors

C. Paarthipan

TITLE
Non-Executive Chairman
AGE
66

Sridhar Ganesan

TITLE
MD & Whole Time Director
COMPENSATION
₹6M
AGE
63
TENURE
5.2 yrs

V. Thirumalai

TITLE
Non-Executive Independent Director
COMPENSATION
₹180K
AGE
77
TENURE
24.8 yrs

D. Mishra

TITLE
Non-Executive Non-Independent Director
COMPENSATION
₹60K
AGE
63
TENURE
11.3 yrs

R. Ravichandran

TITLE
Non-Executive Independent Director
COMPENSATION
₹260K
AGE
61
TENURE
4.9 yrs

K. John

TITLE
Non-Executive Independent Director
COMPENSATION
₹180K
AGE
66
TENURE
4.7 yrs

R. Viswanathan

TITLE
Non-Executive Independent Director
COMPENSATION
₹60K
AGE
66
TENURE
3.9 yrs

K. Prasad

TITLE
Non-Executive Independent Director
COMPENSATION
₹180K
AGE
70
TENURE
4.2 yrs

D. Sathyanarayanan

TITLE
Non-Executive Independent Director
COMPENSATION
₹120K
AGE
59
TENURE
2.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Caplin Point Laboratories insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
22. Feb 19 Buy C. Paarthipan Individual 20. Feb 19 20. Feb 19 10,000 ₹331.40 ₹3,313,982
08. Jun 18 Buy Meera Sridhar Individual 06. Jun 18 06. Jun 18 4,000 ₹393.46 ₹1,573,840
06. Jun 18 Buy Sridhar Ganesan Individual 06. Jun 18 06. Jun 18 8,000 ₹363.00 ₹2,904,000
X
Management checks
We assess Caplin Point Laboratories's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Caplin Point Laboratories has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CAPPL News

Simply Wall St News

Three Things You Should Check Before Buying Caplin Point Laboratories Limited (NSE:CAPPL) For Its Dividend

Dividend paying stocks like Caplin Point Laboratories Limited (NSE:CAPPL) tend to be popular with investors, and for good reason - some research shows that a significant amount of all stock market returns come from reinvested dividends. … Investors might not know much about Caplin Point Laboratories's dividend prospects, even though it has been paying dividends for the last eight years and offers a 0.5% yield. … When buying stocks for their dividends, you should always run through the checks below, to see if the dividend looks sustainable.

Simply Wall St -

Can We See Significant Insider Ownership On The Caplin Point Laboratories Limited (NSE:CAPPL) Share Register?

A look at the shareholders of Caplin Point Laboratories Limited (NSE:CAPPL) can tell us which group is most powerful. … With a market capitalization of ₹29b, Caplin Point Laboratories is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Caplin Point Laboratories

Simply Wall St -

Have Insiders Been Buying Caplin Point Laboratories Limited (NSE:CAPPL) Shares?

So before you buy or sell Caplin Point Laboratories Limited (NSE:CAPPL), you may well want to know whether insiders have been buying or selling. … The Last 12 Months Of Insider Transactions At Caplin Point Laboratories. … In the last twelve months there was more buying than selling by Caplin Point Laboratories insiders

Simply Wall St -

Can Caplin Point Laboratories Limited (NSE:CAPPL) Maintain Its Strong Returns?

Our data shows Caplin Point Laboratories has a return on equity of 35% for the last year. … That means that for every ₹1 worth of shareholders' equity, it generated ₹0.35 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Do Insiders Own Shares In Caplin Point Laboratories Limited (NSE:CAPPL)?

If you want to know who really controls Caplin Point Laboratories Limited (NSE:CAPPL), then you'll have to look at the makeup of its share registry. … Caplin Point Laboratories is not a large company by global standards. … See our latest analysis for Caplin Point Laboratories

Simply Wall St -

Read This Before Selling Caplin Point Laboratories Limited (NSE:CAPPL) Shares

So we'll take a look at whether insiders have been buying or selling shares in Caplin Point Laboratories Limited (NSE:CAPPL). … Caplin Point Laboratories Insider Transactions Over The Last Year. … In the last twelve months there was more buying than selling by Caplin Point Laboratories insiders

Simply Wall St -

Does Caplin Point Laboratories Limited's (NSE:CAPPL) CEO Salary Compare Well With Others?

In 2015 Sridhar Ganesan was appointed CEO of Caplin Point Laboratories Limited (NSE:CAPPL). … How Does Sridhar Ganesan's Compensation Compare With Similar Sized Companies. … Our data indicates that Caplin Point Laboratories Limited is worth ₹30b, and total annual CEO compensation is ₹5.7m.

Simply Wall St -

Here's What Caplin Point Laboratories Limited's (NSE:CAPPL) P/E Ratio Is Telling Us

Caplin Point Laboratories has a P/E ratio of 20.4, based on the last twelve months. … How Do I Calculate Caplin Point Laboratories's Price To Earnings Ratio … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

How Caplin Point Laboratories Limited (NSE:CAPPL) Delivered A Better ROE Than Its Industry

and want to begin learning the link between company’s fundamentals and stock market performance. … Caplin Point Laboratories Limited (NSE:CAPPL) delivered an ROE of 40.04% over the past 12 months, which is an impressive feat relative to its industry average of 11.16% during the same period. … View our latest analysis for Caplin Point Laboratories

Simply Wall St -

Is Caplin Point Laboratories Limited (NSE:CAPPL) Attractive At Its Current PE Ratio?

The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market. … and want to better understand how you can grow your money by investing in Caplin Point Laboratories Limited (NSE:CAPPL). … Caplin Point Laboratories Limited (NSE:CAPPL) trades with a trailing P/E of 21.3x, which is lower than the industry average of 24.3x.

Simply Wall St -

CAPPL Company Info

Description

Caplin Point Laboratories Limited produces, develops, markets, and exports generic formulations and branded products in India and internationally. It provides liquid injections, lyophilised injections, opthalmic products, liquid orals, capsules, tablets, softgel capsules, suppositories and ovules, dry syrups, topicals, inhalers, IV infusion products, dermo cosmetics, and other products, as well as powders for injection. The company was founded in 1990 and is headquartered in Chennai, India.

Details
Name: Caplin Point Laboratories Limited
CAPPL
Exchange: NSEI
Founded: 1990
₹28,512,604,250
75,630,250
Website: http://www.caplinpoint.net
Address: Caplin Point Laboratories Limited
NARBHAVI,
No. 3, Lakshmanan Street,
Chennai,
Tamil Nadu, 600017,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 524742 Equity Shares Mumbai Stock Exchange IN INR 26. Feb 2002
NSEI CAPPL Equity Shares National Stock Exchange of India IN INR 26. Feb 2002
Number of employees
Current staff
Staff numbers
0
Caplin Point Laboratories employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 13:50
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/02/26
Last earnings filing: 2019/02/11
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.